Venoarterial extracorporeal membrane oxygenation or standard care in patients with cardiogenic shock complicating acute myocardial infarction: the multicentre, randomised EURO SHOCK trial
EuroIntervention · 2023-08 · 19 (6) · 482-492
DOI: 10.4244/eij-d-23-00204 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift EuroIntervention, 2023-08. Verfasst von Amerjeet S Banning und 21 weiteren Autor:innen. Beteiligte Einrichtung: Glenfield Hospital, University Hospitals of Leicester NHS Trust, Leicester, UK. Hauptthemen laut MEDLINE: Extracorporeal Membrane Oxygenation, COVID-19, Myocardial Infarction. Die Arbeit wurde bisher 167-mal zitiert (Crossref) und nennt 20 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
BACKGROUND: Cardiogenic shock (CGS) occurs in 10% of patients presenting with acute myocardial infarction (MI), with in-hospital mortality rates of 40-50% despite revascularisation. AIMS: The EURO SHOCK trial aimed to determine if early use of venoarterial extracorporeal membrane oxygenation (VA-ECMO) could improve outcomes in patients with persistent CGS following primary percutaneous coronary intervention (PPCI). METHODS: This multicentre, pan-European trial randomised patients with persistent CGS 30 minutes after PPCI of the culprit lesion to receive either VA-ECMO or continue with standard therapy. The primary outcome measure was 30-day all-cause mortality in an intention-to-treat analysis. Secondary endpoints included 12-month all-cause mortality and 12-month composite of all-cause mortality or rehospitalisation due to heart failure. RESULTS: Due to the impact of the COVID-19 pandemic, the trial was stopped before completion of recruitment, after randomisation of 35 patients (standard therapy n=18, VA-ECMO n=17). Thirty-day all-cause mortality occurred in 43.8% of patients randomised to VA-ECMO and in 61.1% of patients randomised to standard therapy (hazard ratio [HR] 0.56, 95% confidence interval [CI]: 0.21-1.45; p=0.22). One-year all-cause mortality was 51.8% in the VA-ECMO group and 81.5% in the standard therapy arm (HR 0.52, 95% CI: 0.21-1.26; p=0.14). Vascular and bleeding complications occurred more often in the VA-ECMO arm (21.4% vs 0% and 35.7% vs 5.6%, respectively). CONCLUSIONS: Due to the limited number of patients recruited to the trial, no definite conclusions could be drawn from the available data. Our study demonstrates the feasibility of randomising patients with CGS complicating acute MI but also illustrates the challenges. We hope these data will inspire and inform the design of future large-scale trials.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Glenfield Hospital, University Hospitals of Leicester NHS Trust, Leicester, UK.
- Department of Cardiovascular Sciences, University of Leicester, Leicester, UK.
- Consorci Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Cardiovascular Institute, Hospital Clinic, Barcelona, Spain.
- Medizinische Klinik und Poliklinik I, LMU University Hospital Munich, Munich, Germany.
- Department of Cardiology, Deutsches Herzzentrum Muenchen, German Center for Cardiovascular Research (DZHK), Munich, Germany and Partner Site Munich Heart Alliance, Munich, Germany.
- Department of Public Health and Primary Care, KU Leuven, I-BioStat, Leuven, Belgium and UHasselt, I-BioStat, Diepenbeek, Belgium.
Zitieren
APA
Banning, A. S., Sabaté, M., Orban, M., Gracey, J., López-Sobrino, T., Massberg, S., Kastrati, A., Bogaerts, K., Adriaenssens, T., Berry, C., Erglis, A., Haine, S., Myrmel, T., Patel, S., Buera, I., Sionis, A., Vilalta, V., Yusuff, H., Vrints, C., …, & Gershlick, A. H. (2023). Venoarterial extracorporeal membrane oxygenation or standard care in patients with cardiogenic shock complicating acute myocardial infarction: the multicentre, randomised EURO SHOCK trial. EuroIntervention, 19(6), 482-492. https://doi.org/10.4244/eij-d-23-00204
Vancouver
Banning AS, Sabaté M, Orban M, Gracey J, López-Sobrino T, Massberg S, et al. Venoarterial extracorporeal membrane oxygenation or standard care in patients with cardiogenic shock complicating acute myocardial infarction: the multicentre, randomised EURO SHOCK trial. EuroIntervention. 2023;19(6):482-492. doi:10.4244/eij-d-23-00204
BibTeX
@article{Banning2023,
author = {Banning, Amerjeet S and Sabaté, Manel and Orban, Martin and Gracey, Jay and López-Sobrino, Teresa and Massberg, Steffen and Kastrati, Adnan and Bogaerts, Kris and Adriaenssens, Tom and Berry, Colin and Erglis, Andrejs and Haine, Steven and Myrmel, Truls and Patel, Sameer and Buera, Irene and Sionis, Alessandro and Vilalta, Victoria and Yusuff, Hakeem and Vrints, Christiaan and Adlam, David and Flather, Marcus and Gershlick, Anthony H},
title = {Venoarterial extracorporeal membrane oxygenation or standard care in patients with cardiogenic shock complicating acute myocardial infarction: the multicentre, randomised EURO SHOCK trial},
journal = {EuroIntervention},
year = {2023},
volume = {19},
number = {6},
pages = {482--492},
doi = {10.4244/eij-d-23-00204}
}
EUVIMED